ClinicalTrials.gg
RecruitingNCT07158918Updated Sep 8, 2025

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of ABL103 and KEYTRUDA® (pembrolizumab) in Solid Tumors, sponsored by ABL Bio, Inc.. Recruiting at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by ABL Bio, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

ABL Bio, Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must understand and be willing to provide and be able to comply with the study procedures and restrictions.
  • Subjects must be ≥18 years of age on the day of signing the informed consent form (ICF).
  • Subject must have a or cytologically confirmed locally advanced unresectable, or solid tumor.
  • Subject must be or be refractory to available standard therapy or they must be intolerant of available standard therapy.
  • Subject must meet (ECOG) performance status 0 or 1 assessed 7 days before the first administration of the study drug.
  • Subjects must be recovered from AEs from prior therapy to Grade 1 or the baseline grade more than 14 days prior to the first administration of the study drug, except alopecia or Grade 2 toxicities that are deemed stable or irreversible (e.g., peripheral neuropathy)
  • Subjects who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Subject with endocrine-related AEs who are adequately treated with hormone replacement or subjects who have ≤Grade 2 neuropathy are eligible.
  • Subjects must have adequate hematologic, renal, hepatic, and thyroid function at screening and within 7 days prior to the first administration of study drug.
  • Female subjects who are not surgically sterile or must agree to use a highly effective method of (2 methods strongly recommended) during the study and for 6 months following the last dose of ABL103/pembrolizumab.
  • Female subjects of must have a negative serum pregnancy test at screening and within 7 days prior to Cycle 1 Day 1 (C1D1).
  • Male subjects with female partner(s) of childbearing potential must agree to use contraception and and must not donate sperm during the treatment period with ABL103 and taxane and for at least 6 months after the final administration of ABL103 and taxane.
  • Male subjects with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom throughout the study period, and for at least 6 months after the final administration of ABL103 and taxane, and during the partner's pregnancy or breastfeeding period. When using a male condom, the partner must also use an additional method of contraception acceptable for female subjects.

Exclusion criteria

Exclusion Criteria:

  • Subject has received prior anticancer monoclonal antibody treatment or therapy (agent or device) for which the pharmacologic or toxicity profile is not expected to have resolved prior to the first administration of the study drug. A minimum of 28 days is generally recommended for agents with known delayed toxicities or prolonged biological activity, unless otherwise justified.
  • Subject has received prior radiotherapy within 2 weeks of the first administration of study drug, or has radiation-related toxicities, requiring .
  • Subject has received any prior immunotherapy and was discontinued from the treatment due to a Grade 3 or higher irAE (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis.
  • Subject has received radiation therapy to the lung that is >30 Gy within 6 months of the first dose of study treatment.
  • Subject has risk factors for bowel obstruction or bowel perforation, including, but not limited to a history of acute diverticulitis, intra-abdominal abscess, and abdominal carcinomatosis. Subjects with ovarian cancer with a history of abdominal carcinomatosis can be enrolled.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    ABL103 (DL1) + pembrolizumab

    Safety Lead-in Part 1

    Drug: ABL103 · Drug: KEYTRUDA® (pembrolizumab)

  • Experimental
    ABL103 (DL2-1) + pembrolizumab + taxane

    Safety Lead-in Part 2

    Drug: ABL103 · Drug: KEYTRUDA® (pembrolizumab) · Drug: Taxane

  • Experimental
    ABL103 (DL2) + pembrolizumab + taxane

    Safety Lead-in Part 2

    Drug: ABL103 · Drug: KEYTRUDA® (pembrolizumab) · Drug: Taxane

  • Experimental
    Group 1) ABL103 + pembrolizumab + taxane

    Dose-expansion Part

    Drug: ABL103 · Drug: KEYTRUDA® (pembrolizumab) · Drug: Taxane

  • Experimental
    Group 2) ABL103 + pembrolizumab + taxane

    Dose-expansion Part

    Drug: ABL103 · Drug: KEYTRUDA® (pembrolizumab) · Drug: Taxane

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (DLTs)

    Time frame: Day 1 to Day 21 (Safety Lead-in Part 1) and Day 1 to Day 28 (Safety Lead-in Part 2)

  2. Incidence of Treatment-Emergent Adverse Events (TEAEs), Treatment-Related AEs, Serious AEs (SAEs), and Infusion-Related Reactions (IRRs)

    Time frame: From baseline through study completion, an average of 12 months

  3. Recommended Dose for Expansion (RDE) Determination

    Time frame: From baseline through study completion, an average of 12 months

  4. Objective Response Rate (ORR)

    Time frame: Up to approximately 30 months

  5. Disease Control Rate (DCR)

    Time frame: Up to approximately 30 months

Secondary outcomes

  1. Preliminary Objective Response Rate (ORR)

    Time frame: Up to approximately 30 months

  2. Preliminary Disease Control Rate (DCR)

    Time frame: Up to approximately 30 months

  3. Incidence of Anti-Drug Antibodies (ADA)

    Time frame: From baseline through study completion, an average of 12 months

07

Study locations

2 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Sep 8, 2025
StartActual
Aug 6, 2025
Primary completionEst.
Dec 2, 2027
CompletionEst.
Dec 2, 2027
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07158918
Lead sponsor
ABL Bio, Inc.
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Aug 6, 2025
Primary completion
Dec 2, 2027 (estimated)
Completion
Dec 2, 2027 (estimated)
Last update
Sep 8, 2025

Study contacts

Dayoung Ok
Contact
dayoung.ok@ablbio.com
+82-2-3456-7300
Sangmi Lee
study director · ABL Bio

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion